

## Peer Review File

Article information: <https://dx.doi.org/10.21037/cco-23-95>

### Reviewer A

I appreciate the authors on their effort in putting this thoughtful piece together. Maximizing clinical benefit with CAR-T cell therapy in Extra Nodal DLBCL is a real unmet need and something that is being extensively investigated both in the clinical research space as well as at the bench.

**Reply:** Thanks for the kind words

I have some global concerns about the phrasing used by the authors to describe and summarize areas of relevance or concern in their piece.

**Reply:** Thank you for pointing out.

**Comments:** We have revised the text to make it more relevant.

It does across as a piece that was not put together by a seasoned lymphoma specialist/researcher (As it should have). I would highly advise upon the inclusion of a senior lymphoma oncologist/researcher as an author, which will add credibility to the commentary and make it more beneficial for the readership of the journal as well.

**Reply:** This piece already includes a lymphoma specialist/researcher as an author.

I would also encourage the authors to use more supporting evidence or arguments to highlight the concerns regarding suboptimal efficacy of CAR-T in EN DLBCL instead of quoting the reasoning mentioned in the cited manuscripts verbatim.

**Reply:** Sure.

**Comment:** We have added a whole new paragraph highlighting different probable reasons for the suboptimal efficacy of CAR-T in EN DLBCL as an opinion of lymphoma specialist.

### Reviewer B

#### 1. References/Citations

a) References 16 and 17 should be cited between 15 and 18 in order, please revise.

**Reply:** Made the changes

b) Please double-check if more studies should be cited as you mentioned “studies”. OR use “study” rather than “studies”.

Reply: It was studies, have added more citations.

Multiple retrospective studies have attempted to evaluate the outcomes of patients with EN-DLBCL who received CD19-directed CAR-T therapy [14]. However, most of these

## 2. Table 1

It is suggested to use “Author” rather than “Name”.

<u>Name</u>	<u>Year</u>	<u>Type</u>	<u>CAR-T Product</u>	<u>Number of patients EN &amp; N</u>
<u>Katz B et al</u>	<u>2023</u>	<u>Retrospective</u>	<u>Tisagenlecleucel (79.4%) and axicabtagen</u>	<u>72 &amp; 42 (12 no disea</u>

Reply: Made the change.